Melanotan I (Afamelanotide)

Melanotan I

Afamelanotide · Scenesse · [Nle4,D-Phe7]-α-MSH · CUV1647

"The FDA-approved tanning peptide — α-MSH analogue that selectively activates MC1R to increase melanin production without the sexual side effects of Melanotan II (which hits MC4R). Approved as Scenesse for erythropoietic protoporphyria (EPP), a rare condition where sunlight causes extreme pain. Used off-label for photoprotection and tanning by the community."

Type

α-MSH analogue · MC1R-selective

vs Melanotan II

No MC4R activation · no libido/erection effects

Status

UK: prescription-only as Scenesse for EPP · WADA: not specifically listed · US FDA: approved 2019 (Scenesse) for EPP only · off-label tanning use not approved

Form

SubQ implant (Scenesse) or injection (off-label)

Protocol summary

Approved form

Scenesse 16 mg implant

Indication

Erythropoietic protoporphyria (EPP)

Community dose

0.5–1 mg SubQ · loading + maintenance

Community-reported

0.5–1 mg/day SubQ during loading · maintenance 2–3× weekly · cumulative pigment effect

Off-label tanning use is unlicensed; safety profile generally cleaner than Melanotan II (MC1R-selective)

How we read the evidence

FDA-approved (Scenesse) for a rare photosensitivity disorder · NOT approved as a tanning agent · the only melanocortin peptide with regulatory approval · WADA-banned

Animal evidence

Substantial preclinical foundation. Afamelanotide (NDP-MSH, [Nle4-D-Phe7]-α-MSH) is a synthetic 13-amino-acid analog of α-melanocyte-stimulating hormone with substitutions that increase potency and metabolic stability. Mechanism: MC1R agonism stimulates eumelanin synthesis (the dark, photoprotective form of melanin), induces antioxidant pathways, enhances DNA repair, and modulates inflammation. Animal work established the photoprotective and antioxidant effects underlying the EPP indication.

Community & clinical practice

The legitimate community use case is narrow: managed photoprotection for erythropoietic protoporphyria via the Scenesse 16 mg slow-release SubQ implant under specialist supervision. Off-label cosmetic tanning use exists but predates and circumvents the regulatory pathway — research-vendor MT-1 lyophilised powder, typically reconstituted and SubQ-injected at ~0.5–1 mg/day during a loading phase, then maintenance. Pep IQ does not endorse off-label MT-1 cosmetic use: the safety data is in the EPP indication, not in healthy adults seeking tan, and the original developers (Clinuvel) deliberately did not pursue cosmetic-tanning approval.

Human trial data

Strong Phase 3 evidence base for the EPP indication. FDA approval (October 2019) was based on three vehicle-controlled parallel-group trials (NCT01605136 and NCT00979745, plus a US trial) involving 244 adults aged 18–74 across 22 sites in US and Europe, with primary endpoints of pain-free hours in sunlight. EMA approved earlier (2014) under exceptional circumstances with mandatory post-authorisation safety study. Real-world effectiveness data: Wensink et al. 2020 (JAMA Dermatology) reported sustained outcomes in EPP clinical practice. Trials have also explored vitiligo, polymorphic light eruption, solar urticaria, and X-linked protoporphyria — most without leading to additional approvals.

Regulatory status

FDA-approved as Scenesse (afamelanotide) October 2019 — 16 mg subcutaneous implant for adult EPP. EMA-approved 2016. Australian TGA approved 2020. No regulatory approval anywhere for cosmetic tanning, vitiligo (broadly), or any wellness use case. WADA-banned for tested athletes. Off-label sourcing via research-peptide vendors with significant purity variation. Generally well-tolerated in EPP populations — main safety considerations are mole and skin monitoring, hypersensitivity, and the recommendation against use in children (paediatric trials still ongoing in 2026).

Convergence

Melanotan-1 (afamelanotide/Scenesse) is the only melanocortin peptide with regulatory approval anywhere in the world — and that approval is for a specific rare disease (EPP), not for cosmetic tanning. The compound works mechanistically (MC1R-mediated eumelanin synthesis), and the EPP evidence is genuinely solid. Pep IQ flags this honestly: legitimate use is the supervised Scenesse implant for EPP; off-label cosmetic tanning is unapproved everywhere, sourcing is unreliable, and the long-term safety in healthy adults seeking tan is not characterised. If your interest is cosmetic, the regulatory and evidence framework points away from this compound — and the closely related MT-2 carries even more red flags.

Origin & Background

The approved tanning peptide -- and the safer story

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) -- the endogenous peptide that regulates skin pigmentation. Developed at the University of Arizona in the 1980s alongside Melanotan II, the two peptides were designed to increase melanin production for UV protection. Where Melanotan II is a broad melanocortin receptor agonist hitting MC1R, MC3R, MC4R, and MC5R, Melanotan I (afamelanotide) is far more selective for MC1R specifically.

This receptor selectivity is the key clinical distinction. MC4R activation is responsible for the sexual arousal, spontaneous erections, and libido effects that characterise Melanotan II. By not significantly activating MC4R, afamelanotide produces pigmentation without these side effects -- making it suitable for medical use in a broader population including women, men who do not want sexual side effects, and clinical settings where Melanotan II would be inappropriate.

Afamelanotide (Scenesse) was approved by the FDA in October 2019 for erythropoietic protoporphyria (EPP) -- a rare genetic condition where a defect in haem biosynthesis leads to accumulation of protoporphyrin IX, making sunlight exposure intensely painful and causing life-altering photosensitivity. Scenesse is administered as a subcutaneous bioresorbable implant (16mg) that slowly releases afamelanotide over ~60 days, increasing melanin production and providing photoprotection that dramatically reduces EPP patients'' pain episodes. Clinical trials showed a 64% reduction in phototoxic reactions versus placebo.

The community uses injectable afamelanotide off-label for tanning and UV photoprotection -- the same mechanism as Scenesse but at lower doses and via injection rather than implant. The FDA approval provides important validation that the mechanism is real and the compound has an acceptable clinical safety profile.

Science & Mechanism

MC1R selective -- melanin without the side effects

Mechanism of Action

MC1R agonism -- melanogenesis: Afamelanotide binds MC1R on melanocytes with high affinity and selectivity. MC1R activation triggers adenylyl cyclase --> cAMP --> PKA --> MITF (microphthalmia-associated transcription factor) --> upregulation of tyrosinase and TYRP1/TYRP2 (melanin synthesis enzymes). The result: increased eumelanin (brown/black melanin) production, which provides UV protection by absorbing and scattering UV radiation.

Eumelanin vs phaeomelanin: MC1R activation shifts the melanin type from phaeomelanin (red/yellow, provides less UV protection, may actually increase oxidative DNA damage under UV) toward eumelanin (brown/black, absorbs UV, provides genuine photoprotection). This shift is the therapeutic mechanism in EPP and the cosmetic mechanism for tanning. Fair-skinned individuals with naturally high phaeomelanin-to-eumelanin ratios benefit most.

No MC4R activation -- no sexual effects: The structural modifications in afamelanotide (most notably [Nle4,D-Phe7] substitutions) provide selectivity for MC1R. Unlike Melanotan II, afamelanotide does not significantly activate MC4R in the hypothalamus -- the receptor responsible for Melanotan II''s sexual arousal and erection-inducing effects. This makes afamelanotide a pigmentation-specific compound.

Sustained release from implant (Scenesse): The approved Scenesse formulation is a bioresorbable poly(DL-lactide-co-glycolide) implant that releases afamelanotide over approximately 60 days. This provides sustained MC1R stimulation for continuous melanin upregulation over the summer photoprotection window for EPP patients -- a clinically practical sustained-release approach.

Injectable off-label pharmacokinetics: Community injection of afamelanotide produces a peak-and-trough plasma profile rather than the sustained release of the implant. Most users report visible pigmentation effects within 3-5 days of first injection, with peak tanning at 7-14 days. The duration depends on dose and individual melanocyte response.

Things to know

Safety -- FDA-approved means real data

Mild

Nausea and injection site reactions -- most common adverse events in clinical trials. Nausea typically resolves within hours. Injection site bruising and swelling with SubQ administration.

Moderate

Nevi (mole) darkening and new nevi -- afamelanotide stimulates melanocytes broadly. Existing nevi can darken and become more irregular. New nevi can develop. Dermatological monitoring (dermoscopy annually) is recommended for anyone using afamelanotide regularly. Any rapidly changing lesion warrants immediate dermatological assessment.

Mild

Flushing and fatigue -- transient, dose-dependent. Less severe than with Melanotan II. Usually resolves within hours of administration.